← Leaderboards
Stefan Neubauer
University Of Virginia
$7,234,062
Attributed
$14,468,124
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.8M · FY2013–17$5M$3.8M$2.5M$1.3M$0
'13
'14
'15
'16
'17
Funding mix
By agency
NIH$14,468,124 · 1
By mechanism
U01$14,468,124 · 1
Top collaborators
- Christopher M Kramer5 shared
Most similar at University Of Virginia
Same institution · by research overlap
- Richard J Price$15,866,868
- Justin S. Hanes$23,093,683
- John N Campbell$3,297,983
- Avril V. Somlyo$10,788,474
- Jamieson Macdonald Bourque$1,344,957
Others in their field
Top investigators on “Disease Phenotype”
- Constance Ann Benson · University Of California, San Diego$187,132,366
- Richard A Gibbs · Baylor College Of Medicine$186,551,214
- Ralph Parchment · Leidos Biomedical Research, Inc.$141,315,269
- David M Nathan · Massachusetts Institute Of Technology$140,596,299
- James E. Gern · University Of Wisconsin-Madison$139,483,313
- John M Lachin · George Washington University$136,050,105
Research focus
Disease PhenotypeDiffuseAdverse EventDeath, Sudden, CardiacDiagnosisCardiac DeathAutosomal Dominant TraitAffectBiological MarkersCessation Of LifeCardiacAtrial FibrillationClinical RiskClinical TrialsClinical Trials DesignCohortCollagenCollectionCardiovascular SystemCostCost EffectiveCox ModelsData MiningEdema
Grant awards (5)
HCMR Novel Markers of Prognosis in Hypertrophic Cardiomyopathy$3,787,327
U01 · FY2017 · HL
HCMR Novel Markers of Prognosis in Hypertrophic Cardiomyopathy$2,829,326
U01 · FY2016 · HL
HCMR Novel Markers of Prognosis in Hypertrophic Cardiomyopathy$1,151,474
U01 · FY2015 · HL
HCMR Novel Markers of Prognosis in Hypertrophic Cardiomyopathy$3,332,510
U01 · FY2014 · HL
HCMR Novel Markers of Prognosis in Hypertrophic Cardiomyopathy$3,367,487
U01 · FY2013 · HL